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Abstract
As part of a World Health Organization-led effort to update the empirical evidence base for the leishmaniases, national
experts provided leishmaniasis case data for the last 5 years and information regarding treatment and control in their
respective countries and a comprehensive literature review was conducted covering publications on leishmaniasis in 98
countries and three territories (see ‘Leishmaniasis Country Profiles Text S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, S13,
S14, S15, S16, S17, S18, S19, S20, S21, S22, S23, S24, S25, S26, S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S38, S39,
S40, S41, S42, S43, S44, S45, S46, S47, S48, S49, S50, S51, S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63, S64, S65,
S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82, S83, S84, S85, S86, S87, S88, S89, S90, S91,
S92, S93, S94, S95, S96, S97, S98, S99, S100, S101’). Additional information was collated during meetings conducted at WHO
regional level between 2007 and 2011. Two questionnaires regarding epidemiology and drug access were completed by
experts and national program managers. Visceral and cutaneous leishmaniasis incidence ranges were estimated by country
and epidemiological region based on reported incidence, underreporting rates if available, and the judgment of national
and international experts. Based on these estimates, approximately 0.2 to 0.4 cases and 0.7 to 1.2 million VL and CL cases,
respectively, occur each year. More than 90% of global VL cases occur in six countries: India, Bangladesh, Sudan, South
Sudan, Ethiopia and Brazil. Cutaneous leishmaniasis is more widely distributed, with about one-third of cases occurring in
each of three epidemiological regions, the Americas, the Mediterranean basin, and western Asia from the Middle East to
Central Asia. The ten countries with the highest estimated case counts, Afghanistan, Algeria, Colombia, Brazil, Iran, Syria,
Ethiopia, North Sudan, Costa Rica and Peru, together account for 70 to 75% of global estimated CL incidence. Mortality data
were extremely sparse and generally represent hospital-based deaths only. Using an overall case-fatality rate of 10%, we
reach a tentative estimate of 20,000 to 40,000 leishmaniasis deaths per year. Although the information is very poor in a
number of countries, this is the first in-depth exercise to better estimate the real impact of leishmaniasis. These data should
help to define control strategies and reinforce leishmaniasis advocacy.
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Introduction
Although estimated to cause the ninth largest disease burden
among individual infectious diseases, leishmaniasis is largely
ignored in discussions of tropical disease priorities [1,2]. This
consignment to critical oblivion results from its complex epidemi-
ology and ecology, the lack of simple, easily-applied tools for case
management and the paucity of current incidence data, and often
results in a failure on the part of policy-makers to recognize its
importance [3,4]. Based on the World Health Assembly Resolu-
tion 2007/60.13, the World Health Organization (WHO)
convened the Expert Committee on Leishmaniasis in March
2010, which subsequently issued the first updated technical report
on leishmaniasis in more than 20 years [5,6]. Both the WHA
Resolution and the Expert Committee report highlighted the need
to update the epidemiological evidence base in order to plan
appropriate approaches to the control of leishmaniasis.
Estimates of disease burden are widely used by policy-makers
and funding organizations to establish priorities [7,8,9,10]. These
estimates are most commonly expressed as disability-adjusted life
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World Development Report and the focus of intense scrutiny ever
since [11,12,13]. The accuracy of this measure depends on the
reliability of the incidence, duration, severity and mortality data
for a given condition, as well as the underlying assumptions used in
the calculations [7,14]. Although a new round of global disease
burden estimation is currently underway, empirical data collection
and field validation are neither included nor supported as part of
the exercise [15].
The evidence base for the neglected tropical diseases (NTDs) is
acknowledged to be particularly problematic [9,16]. Leishmani-
asis, like many other NTDs, occurs in a focal distribution and in
remote locations, making extrapolation from official data sources
difficult [4]. Visceral leishmaniasis (VL) results in death if not
treated, the majority of leishmaniasis deaths go unrecognized, and
even with treatment access, VL may result in case-fatality rates of
10–20% [17,18,19,20,21,22]. Reported leishmaniasis case figures
are widely acknowledged to represent gross underestimates of the
true burden, but studies that measure the degree of underreporting
are rare [23]. As part of the WHO effort to update the
leishmaniasis evidence base, a series of regional meetings were
held. National program managers and expert professionals were
asked to provide detailed information on epidemiology, ecology,
geographical distribution and trends, drug access and manage-
ment of leishmaniasis for their respective countries. These data,
accompanied by literature reviews, are compiled in extensive
profiles of each endemic country or territory in the Annex of this
publication (see ‘Leishmaniasis Country Profiles Text S1, S2, S3,
S4, S5, S6, S7, S8, S9, S10, S11, S12, S13, S14, S15, S16, S17,
S18, S19, S20, S21, S22, S23, S24, S25, S26, S27, S28, S29, S30,
S31, S32, S33, S34, S35, S36, S37, S38, S39, S40, S41, S42, S43,
S44, S45, S46, S47, S48, S49, S50, S51, S52, S53, S54, S55, S56,
S57, S58, S59, S60, S61, S62, S63, S64, S65, S66, S67, S68, S69,
S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82,
S83, S84, S85, S86, S87, S88, S89, S90, S91, S92, S93, S94, S95,
S96, S97, S98, S99, S100, S101’). This paper focuses on an
analysis of the findings, and estimates of leishmaniasis incidence
derived from the epidemiological data.
Methods
From 2007 to 2010, WHO organized a series of regional
meetings (EMRO countries, Geneva 2007; PAHO countries,
Medellin 2008; EURO countries, Istanbul 2009; AFRO countries,
Addis Ababa 2010; SEARO countries, Paro 2011). In preparation
for each meeting, country representatives were asked to provide
yearly reported VL and cutaneous leishmaniasis (CL) incidence
data for at least the last 5 years prior to the meeting. In addition,
an electronic epidemiological questionnaire was sent to the
national control program managers and/or to reputable national
scientists to fill information gaps. Data collected included
administrative divisions affected, whether VL and CL case
notification is mandatory, characteristics of known reservoirs and
vector control programs, estimated and reported case numbers,
and outbreaks in the previous 5 years.
A comprehensive literature search was also conducted, and the
resulting information was used as an independent validation of
Table 1. Reported and estimated incidence of visceral leishmaniasis in the American region.
Reported VL cases/year Years of report Estimated annual VL incidence
Argentina 8 2004–2008 20 to 30
1
Bolivia 0 2008
Brazil 3481 2003–2007 4200 to 6300
2
Colombia 60 2004–2008 70 to 110
2
El Salvador no data
Guatemala 15 2004–2008 20 to 30
2
Honduras 6 2004–2008 7 to 10
2
Mexico 7 2004–2008 8 to 12
2
Nicaragua 3 2003–2007 3 to 5
2
Paraguay 48 2004–2008 100 to 200
1
Venezuela 40 2004–2008 50 to 70
2
Region 3668 4500 to 6800
1Underreporting considered moderate (2–4-fold) based on recent introduction of VL into the country.
2Underreporting considered mild (1.2–1.8-fold) based on data from Brazil [25].
doi:10.1371/journal.pone.0035671.t001
Table 2. Reported and estimated incidence of visceral
leishmaniasis in the sub-Saharan African region.
Reported VL
cases/year
Years of
report
Estimated annual
VL incidence
Central African
Republic
no data
Cameroon no data
Chad no data
Cote d’Ivoire 0 2004–2008
DR Congo 0 2004–2008
Gambia no data
Mauritania no data
Niger no data
Nigeria 1 2004–2008
Senegal 0 2004–2008
Zambia no data
Region 1
doi:10.1371/journal.pone.0035671.t002
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searches using the terms leishmaniasis and epidemiology with the name
of each endemic country or territory. For the initial search, we
included all articles listed in MEDLINE in English, French,
Table 3. Reported and estimated incidence of visceral leishmaniasis in the East African region.
Reported VL cases/year Years of report Estimated annual VL incidence
Djibouti no data
Eritrea 100 2008 200 to 400
1
Ethiopia 1860 2004–2008 3700 to 7400
1
Kenya 145 2004–2008 610 to 1200
2
Somalia 679 2009 1400 to 2700
1
Sudan 3742 2005–2009 15,700 to 30,300
2
South Sudan 1756 2004–2008 7400 to 14,200
2
Uganda 288 2004–2008 350 to 520
3
Region 8569 29,400 to 56,700
1Underreporting considered moderate (2–4-fold).
2Underreporting considered severe (4.2–8.1-fold).
3Underreporting considered mild (1.2–1.8).
doi:10.1371/journal.pone.0035671.t003
Table 4. Reported and estimated incidence of visceral leishmaniasis in the Mediterranean region.
Reported VL cases/year Years of report Estimated annual VL incidence
Albania 114 2004–2008 140 to 210
1
Algeria 111 2004–2008 130 to 200
1
Bosnia and Herzegovina 2 2002–2005 2 to 3
1
Bulgaria 7 2004–2008 8 to 12
1
Croatia 5 2004–2008 6 to 8
1
Cyprus 2 2008 2 to 4
1
Egypt 1 2008 1 to 2
1
France 18 2004–2008 20 to 30
1
Greece 42 2004–2008 50 to 80
1
Israel 2 2003–2007 3 to 4
1
Italy 134 2003–2007 160 to 240
1
Jordan 0 2004–2008 0 to 0
Lebanon 0 2004–2008 0 to 0
Libya 3 2004–2008 5 to 10
2
Macedonia 7 2005–2009 9 to 13
1
Malta 2 2002–2005 3 to 4
1
Monaco no data
Montenegro 3 2004–2008 4 to 5
1
Morocco 152 2004–2008 300 to 610
2
Palestine 5 2004–2008 10 to 20
2
Portugal 15 2003–2007 20 to 30
1
Slovenia no data
Spain 117 2004–2008 140 to 210
1
Syria 14 2004–2008 30 to 60
2
Tunisia 89 2004–2008 110 to 160
1
Turkey 29 2003–2007 60 to 120
2
Region 875 1200 2000
1Underreporting considered mild (1.2–1.8-fold).
2Underreporting considered moderate (2–4-fold).
doi:10.1371/journal.pone.0035671.t004
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conducted. We selected articles that explicitly addressed incidence,
geographic distribution, surveillance and/or trends over time, and
preferentially chose articles published since 2000 if available. For
countries with sparse data on leishmaniasis, we broadened the
review to include all articles that shed light on the occurrence of
the disease within that country. We reviewed titles for all
references, abstracts when available for those whose titles were
not sufficient to lead us to exclude the paper, and the full article
when the abstract indicated possible relevance. The search for
country-specific literature yielded 3242 potentially relevant arti-
cles, of which 340 were retained based on our selection criteria.
Five recent review articles were also included. Twenty-six
additional unpublished reports were provided by national or
international experts. The literature was reviewed by at least
2 authors and regular meetings were held among the authors to
discuss the findings in depth.
A MEDLINE search was also performed using the terms
leishmaniasis and underreporting to identify articles that would aid in
making incidence estimates. This search yielded 8 articles of which
5 presented data on the magnitude of leishmaniasis underreport-
ing. One additional article was identified from author literature
collections, yielding 3 articles with empirical data regarding VL
and 3 for CL underreporting [24,25,26,27,28,29]. These articles
were used to establish probable degrees of underreporting for the
countries in which their analyses were performed, and were also
used for estimates in countries judged similar in their degree of
underreporting. National and international experts provided their
judgements of the magnitude of underreporting. In addition, for
countries where reporting is sparse, but surveys have been
performed, the published data were used as a basis to select the
Table 5. Reported and estimated incidence of visceral leishmaniasis in the Middle East to Central Asia.
Reported VL cases/year Years of report Estimated annual VL incidence
Afghanistan no data
Armenia 7 2004–2008 10 to 30
1
Azerbaijan 28 2004–2008 60 to 110
1
China 378 2004–2008 760 to 1500
1
Georgia 164 2004–2008 330 to 660
1
Iran (Islamic Republic of) 149 2004–2008 300 to 600
1
Iraq 1711 2004–2008 3400 to 6800
1
Kazakhstan 1 2004–2008 2 to 4
1
Kyrgyzstan 0 2004–2008
Oman 1 2004–2008 2 to 4
1
Pakistan no data
Saudi Arabia 34 2004–2008 40 to 60
2
Tajikistan 15 2004–2008 30 to 60
1
Turkmenistan 0 2004–2008
Ukraine 2 2005–2008 4 to 7
1
Uzbekistan 7 2004–2008 10 to 30
1
Yemen 0 2004–2008 20 to 50
1
Region 2496 5000 10,000
1Underreporting considered moderate (2–4-fold).
2Underreporting considered mild (1.2–1.8).
doi:10.1371/journal.pone.0035671.t005
Table 6. Reported and estimated incidence of visceral leishmaniasis in the Indian subcontinent and Southeast Asia.
Reported VL cases/year Years of report Estimated annual VL incidence
Bangladesh 6224 2004–2008 12,400 to 24,900
1
Bhutan 2 2005–2009 10 to 20
2
India 34,918 2004–2008 146,700 to 282,800
3
Nepal 1477 2004–2008 3000 to 5900
1
Sri Lanka no data 6 to 10
4
Thailand 2 2006–2010 5 to 10
5
Region 42,623 162,100 to 313,600
1Underreporting considered moderate (2.0–4.0-fold; based on lower proportion of cases treated in private sector compared to India).
2Underreporting range based on 2 assessments in Bihar [27,28].
doi:10.1371/journal.pone.0035671.t006
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estimated plausible VL and CL incidence ranges were assigned by
country and/or region based on reported incidence and multipli-
cation by the probable underreporting factors. Estimates less than
20 were retained as the precise product of the reported case
number times the underreporting factor, those between 20 and
1000 were rounded to the nearest 10 and those over 1000 were
rounded to the nearest 100. Where reporting was absent but
Table 7. Reported and estimated incidence of cutaneous leishmaniasis in the American region.
Reported CL cases/year Years of report Estimated annual CL incidence
Argentina 261 2004–2008 730 to 1200
1
Belize no data
Bolivia 2647 2004–2008 7400 to 12,200
1
Brazil 26,008 2003–2007 72,800 to 119,600
1
Colombia 17,420 2005–2009 48,800 to 80,100
1
Costa Rica 1249 2002–2006 3500 to 5700
1
Dominican Republic no data 0 to 0
Ecuador 1724 2004–2008 4800 to 7900
1
El Salvador no data 0 to 0
French Guyana 233 2004–2008 650 to 1100
1
Guatemala 684 2004–2008 1900 to 3100
1
Guyana 16 2006–2008 50 to 70
1
Honduras 1159 2006–2008 3200 to 5300
1
Mexico 811 2004–2008 2300 to 3700
1
Nicaragua 3222 2003–2007 9000 to 14,800
1
Panama 2188 2005–2009 6100 to 10,100
1
Paraguay 431 2004–2008 1200 to 2000
1
Peru 6405 2004–2008 17,900 to 29,500
1
Suriname 3 2005–2007 8 to 14
1
Venezuela 2480 2004–2008 6900 to 11,400
1
REGION 66,941 187,200 307,800
1Underreporting considered mild (2.8–4.6-fold) based on data from Argentina [29].
doi:10.1371/journal.pone.0035671.t007
Table 8. Reported and estimated incidence of cutaneous leishmaniasis in the sub-Saharan African region.
Reported CL cases/year Years of report Estimated annual CL incidence
Burkina Faso no data
Cameroon 55 2007–2009 280 to 550
1
Chad no data
Cote d’Ivoire 1 2004–2008 5 to 10
1
DR Congo 0 2009
Ghana 27 2004–2008 140 to 270
1
Guinea no data
Guinea-Bissau no data
Mali 58 2004–2008 290 to 580
1
Mauritania no data
Namibia no data
Niger no data
Nigeria 5 2004–2008 30 to 50
1
Senegal 8 2004–2008 40 to 80
1
South Africa no data
REGION 155 790 to 1500
1
1Underreporting considered moderate (5–10-fold).
doi:10.1371/journal.pone.0035671.t008
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based on the judgment of national and international experts. The
regional estimates represent the sum of the country estimates
followed by the same rounding process. Similarly, the global
estimates represent the sum of the regional estimates followed by
rounding as described above. In order to facilitate expert judgment
regarding the probable accuracy of the figures presented here, we
defined geographical regions consistent with the major ecological
foci of leishmaniasis transmission, rather than official WHO
regions [31,32,33].
Table 9. Reported and estimated incidence of cutaneous leishmaniasis in the East African region.
Reported CL cases/year Years of report Estimated annual CL incidence
Djibouti no data
Eritrea 50 2008 250 to 500
1
Ethiopia no data 20,000 to 50,000
2
Kenya no data
Sudan no data 15,000 to 40,000
3
South Sudan no data
REGION 50 35,300 to 90,500
1Underreporting considered moderate (5–10-fold).
2Based on conference report (Armauer Hansen Research Institute, Federal Ministry of Health of Ethiopia and World Health Organization. Consultative meeting for the
control of cutaneous leishmaniasis in Ethiopia; June 4–5, 2011; Addis Ababa, Ethiopia).
3Based on estimates by Dr. Nuha Hamid, national project officer, WHO-Khartoum, Sudan (see Annex).
doi:10.1371/journal.pone.0035671.t009
Table 10. Reported and estimated incidence of cutaneous leishmaniasis in the Mediterranean.
Reported CL cases/year Years of report Estimated annual CL incidence
Albania 6 2004–2008
Algeria 44,050 2004–2008 123,300 to 202,600
1
Bosnia and Herzegovina 0 2008
Bulgaria 0 2008
Croatia 2 2004–2008 6 to 10
1
Cyprus 1 2006–2008
Egypt 471 2008 1300 to 2200
1
France 2 2004–2008 6 to 10
1
Greece 3 2004–2008 8 to 13
1
Israel 579 2003–2007 1600 to 2700
1
Italy 49 2003–2007 140 to 230
1
Jordan 227 2004–2008 630 to 1000
1
Lebanon 0 2004–2008
Libya 3540 2004–2008 9900 to 16,300
1
Macedonia 0 2008
Malta 0 2008
Monaco no data
Montenegro 0 2008
Morocco 3430 2004–2008 9600 to 15,800
1
Palestine 218 2005–2009 610 to 1000
1
Portugal 0 2004–2008
Slovenia no data
Spain 0 2004–2008
Syria 22,882 2004–2008 64,100 to 105,300
1
Tunisia 7631 2004–2008 21,400 to 35,100
1
Turkey 2465 2003–2007 6900 to 11,300
1
REGION 85,555 239,500 393,600
1Underreporting considered mild (2.8–4.6) [29].
doi:10.1371/journal.pone.0035671.t010
Leishmaniasis Worldwide and Estimates of Incidence
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e35671A second questionnaire addressed access to antileishmanial
medicines, and included specific questions: whether the public
sector provides health care free of charge; the existence of a
national program for control of leishmaniasis; inclusion of
antileishmanial medicines in the National Essential Drug List;
the number of different medicines purchased for the public sector
or donations received in the last two years; sale of antileishmanial
drugs in the private sector and price per tablet or vial; percentage
of people using the for-profit private sector versus public sector for
leishmaniasis treatment; health care level providing treatment in
the public sector; presence of NGOs or other non-profit agencies
providing leishmaniasis treatment; and barriers to access for
treatment of leishmaniasis. Basic social and health data from each
country were obtained from the websites of the relevant
international agencies [34,35,36,37,38].
The epidemiological data were used to produce maps with 2008
as the reference year using ArcGIS 9.3– Desktop (Esri, Redlands,
CA) and following WHO guidelines for GIS usage. The numbers
of confirmed cases by clinical form (VL, CL, mucocutaneous
leishmaniasis) were mapped by official first level administrative
division. These data were used to calculate annual incidence rates.
A single standard range of values was used for each clinical form to
facilitate visual comparison between countries. Draft maps were
shared with data providers and other leishmaniasis experts for
validation. The following maps were developed for each country:
situational map with neighbouring countries and world globe,
maps of cases by clinical form, and maps of incidence per 10,000
inhabitants. All maps follow a consistent set of characteristics: five
categories of colours in a yellow-to-red scale were chosen for the
maps of cases, and six categories of colours in blue tones scale were
chosen for the maps of incidence. The sparse information in a few
countries required the use of ad hoc scales. Only WHO GIS
shapefile databases were used; the maps follow the administrative
limits and frontiers recognized by United Nations conventions.
The parasitological information has been reproduced from the
WHO Technical Report Series 949 (http://whqlibdoc.who.int/
trs/WHO_TRS_949_eng.pdf) published in 2010.
Table 11. Reported and estimated incidence of cutaneous leishmaniasis in the Middle East to Central Asia.
Reported CL cases/year Years of report Estimated annual CL incidence
Afghanistan 22,620 2003–2007 113,100 to 226,200
1
Armenia 0 2008
Azerbijan 17 2004–2008 50 to 80
2
China 0 2004–2008
Georgia 5 2004–2008
Iran (Islamic Republic of) 24,630 2004–2008 69,000 to 113,300
2
Iraq 1655 2004–2008 8300 to 16,500
3
Kazakhstan 15 2004–2008 40 to 70
2
Kyrgyzstan 0 2004–2008
Mongolia no data
Oman 5 2004–2008 15 to 20
2
Pakistan 7752 2004–2008 21,700 to 35,700
2
Saudi Arabia 3445 2004–2008 9600 to 15,800
2
Tajikistan 25 2007–2008 125 to 250
3
Turkmenistan 99 2004–2008 490 to 990
3
Ukraine 2 2004–2008 10 to 20
3
Uzbekistan 142 2004–2008 710 to 1400
3
Yemen 603 2005–2009 3000 to 6000
3
REGION 61,013 226,200 416,400
1Underreporting considered moderate (5–10-fold) based on estimates of incidence from population-based surveys [30].
2Underreporting considered mild (2.8–4.6) [29].
3Underreporting considered moderate (5–10-fold).
doi:10.1371/journal.pone.0035671.t011
Table 12. Reported and estimated incidence of cutaneous leishmaniasis in the Indian subcontinent.
Reported CL cases/year Years of report Estimated annual CL incidence
India 156 2005–2009 1000 to 2000
1
Sri Lanka 322 2004–2008 900 to 1500
2
REGION 478 1900 to 3500
1Based on estimates by Dr RA Bumb, Department of Skin, STD and Leprosy, SP Medical College, Bikaner, Rajasthan, India.
2Underreporting considered mild (2.8–4.6) [29].
doi:10.1371/journal.pone.0035671.t012
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the magnitude of underreporting, maps, data regarding epidemi-
ology, case load, access to treatment and access to drugs, and
parasitological information are presented in a series of extensive
Profiles of each endemic individual country and territory and are
presented in the Annex of this publication (see ‘Leishmaniasis
Country Profiles Text S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11,
S12, S13, S14, S15, S16, S17, S18, S19, S20, S21, S22, S23, S24,
S25, S26, S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37,
S38, S39, S40, S41, S42, S43, S44, S45, S46, S47, S48, S49, S50,
S51, S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63,
S64, S65, S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76,
S77, S78, S79, S80, S81, S82, S83, S84, S85, S86, S87, S88, S89,
S90, S91, S92, S93, S94, S95, S96, S97, S98, S99, S100, S101’).
Results
A total of 98 countries and 3 territories on 5 continents reported
endemic leishmaniasis transmission (Tables 1, 2, 3, 4, 5, 6 and 7, 8,
9, 10, 11, 12). In total, official case counts totalled more than
58,000 VL cases and 220,000 CL cases per year (Tables 13 and
14). However, only about two-thirds of countries had reported
incidence data for a five-year period; data were sparsest for the foci
in Africa. A number of countries are listed here as endemic despite
the lack of reported human cases, usually reflecting an absence of
surveillance or other investigations. [39] For example, although
Mongolia has not reported human CL cases, L. major genetically
identical to that found in countries with proven endemic
transmission has been isolated on multiple occasions from gerbils.
[40] Only countries with circulating species known to be
pathogenic to humans are included as endemic. For this reason,
Australia is not considered endemic despite reports of CL among
red kangaroos caused by a newly described leishmanial species.
[41] Human infections due to lower trypanosomatids are also
excluded. [42].
There are few published empirical assessments of underreport-
ing in official surveillance data. Two studies from Bihar, India,
compared VL case numbers ascertained through active house-to-
house surveys to those reported in the official surveillance system;
official figures were shown to be 4.2-fold and 8.1-fold lower than
the incidence found by active case detection in the two studies,
respectively. [27,28] A study in Brazil used the capture-recapture
method to estimate underreporting of VL, based on data from 3
different sources; the degree of underreporting was found to be
1.3- to 1.7-fold. [25] Data from one province in Argentina
estimated the degree of CL underreporting to be 2.8 to 4.6-fold;
however, studies from Guatemala and Jordan indicate that CL
incidence may be underestimated by 40- to 47-fold in national
surveillance data. [24,26,29] Based on these publications, country-
level VL underreporting magnitude was categorized as follows:
mild (1.2- to 1.8-fold based on data from Brazil [25]); severe (4.0-
to 8.0-fold based on data from India [27,28]); and an intermediate
category of moderate (2.0 to 4.0-fold) underreporting. Despite the
high published range of CL underreporting [24,26], we chose
conservative multipliers: mild (2.8 to 4.6-fold based on data from
Argentina [29]) and moderate (5.0- to 10.0-fold). No estimates
could be made for most countries in sub-Saharan Africa, where
almost no data were available.
Based on these estimates, approximately 0.2 to 0.4 million VL
cases and 0.7 to 1.2 million CL cases occur each year. More than
Table 13. Global reported and estimated incidence of visceral leishmaniasis.
Reported VL cases/year
Countries with 5 years of
data Estimated annual VL incidence
Americas 3662 8/11 (73%) 4500 to 6800
Sub-Saharan Africa 1 3/11 (27%)
East Africa 8569 5/8 (63%) 29,400 to 56,700
Mediterranean 875 21/26 (81%) 1200 to 2000
Middle East to Central Asia 2496 14/17 (82%) 5000 to 10,000
South Asia 42,623 3/6 (50%)* 162,100 to 313,600
Global total 58,227 54/79 (68%) 202,200 to 389,100
*3/3 (100%) of high burden countries (India, Bangladesh, Nepal) reported 5 years of data. Reports incomplete for Sri Lanka, Bhutan and Thailand.
doi:10.1371/journal.pone.0035671.t013
Table 14. Global reported and estimated incidence of cutaneous leishmaniasis.
Reported CL
cases/year
Countries with 5 years
of data Estimated annual CL incidence
Americas 66,941 14/20 (70%) 187,200 to 307,800
Sub-Saharan Africa 155 5/15 (33%) 770 to 1500
East Africa 50 0/6 (0%) 35,300 to 90,500
Mediterranean 85,555 17/26 (65%) 239,500 to 393,600
Middle East to Central Asia 61,013 16/18 (89%) 226,200 to 416,400
South Asia 322 2/2 (100%) 1900 to 3500
Global total 214,036 53/87 (61%) 690,900 to 1,213,300
doi:10.1371/journal.pone.0035671.t014
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Bangladesh, Sudan, South Sudan, Brazil and Ethiopia (Table 13).
Cutaneous leishmaniasis is more widely distributed, with about
one-third of cases occurring in each of three regions, the Americas,
the Mediterranean basin, and western Asia from the Middle East
to Central Asia (Table 14). The ten countries with the highest
estimated case counts, Afghanistan, Algeria, Colombia, Brazil,
Iran, Syria, Ethiopia, North Sudan, Costa Rica and Peru, together
account for 70 to 75% of global estimated CL incidence.
Mortality data are extremely sparse and generally represent
hospital-based deaths only. The reported case-fatality rate for VL in
Brazil in 2006 was 7.2%. In the Indian subcontinent, the focus
responsible for the largest proportion of global VL cases, reported
case-fatalityrates rangedfrom 1.5%(93deaths/6224 VLcasesfrom
2004–2008) in Bangladesh to 2.4% (853/34,918) in India and 6.2%
(91/1477) in Nepal. However, community-based studies that
included active searches for deaths due to kala-azar estimate case-
fatality rates of more than 10%, while data from a village-based
study in India suggest that as many as 20% of VL patients,
disproportionately poor and female, died before their disease was
recognized. [43,44,45] In South Sudan, one community-based
longitudinal study demonstrated a case-fatality rate of 20% in a
settled village in peacetime; in areas of conflict, famine or
population displacement mortality rates are much higher. [22,46]
A recent study from South Sudan estimated that 91% of all kala-
azar deaths went unrecognized. [47] Using an overall case-fatality
rate of 10% and assuming that virtually all deaths are from VL, we
reach a tentative estimate of 20,000 to 40,000 leishmaniasis deaths
per year, in line with previous WHO estimates. [10]
Discussion
The data presented here and in the accompanying Annex (see
‘Leishmaniasis Country Profiles Text S1–S101’) represent the first
update of the empirical database for leishmaniasis since 1991.
[48,49] We are acutely cognizant of the uncertainties inherent in
the data, and for that reason, have presented rough ranges rather
than single estimates for each outcome. We deliberately used
conservative assumptions for the underreporting rates and
resultant multipliers; true leishmaniasis incidence rates may be
substantially higher. Due to the lack of data, we made no estimates
for post-kala-azar dermal leishmaniasis, mucocutaneous leishman-
iasis, and other less frequent forms of leishmaniasis. Our mortality
estimate contains even more uncertainty than the incidence
estimate, because studies affirm that a large proportion of kala-
azar deaths occur outside of health facilities and the cause likely
never recognized, precluding the possibility of accurate passive
reporting. [43,45,47].
The limitations of these data are obvious: surveillance and vital
records reporting in the countries most affected by leishmaniasis
are incomplete, and we have very sparse data on which to base
correction factors for underreporting. The figures in this report
should not be considered precise and should be interpreted with
caution. Nevertheless, these data include a more comprehensive
review of leishmaniasis incidence than any previous publication,
and represent a major improvement in the evidence base for one
of the most neglected diseases. [50] Better surveillance systems are
urgently needed, in particular in disease foci targeted for more
intensive control or elimination. [4,51] Many key measures of
progress, such as validation of trends seen in surveillance data and
accurate case-fatality rates, can only be obtained through the
active collection of community-based data. [4,52] We hope the
data presented here will allow a more nuanced interpretation of
published disease burden estimates, and the uncertainties in these
data will spur activities to improve the evidence base for
leishmaniasis and other neglected diseases.
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